RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the Symposium on Clinical Interventional Oncology ("CIO") which is being held September 20-22, 2024, at the Loews Hotel in Miami Beach, Florida. Dr. Gandhi's presentation will highlight RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer ("LAPC") and recent publications of clinical data.
Dr. Gandhi, professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine, is a Course Director for the Symposium on CIO. Since 2018, Dr. Gandhi has been instrumental as a principal investigator for the Miami Cancer Institute in RenovoRx's pivotal ongoing Phase III TIGeR-PaC clinical trial in LAPC.
Dr. Gandhi's presentation will provide an overview of the clinical challenges of the standard of care treatment available to LAPC patients. Systemic (intravenous) chemotherapy, while considered the standard-of-care for LAPC, is often associated with debilitating side effects, and may have limited effectiveness in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy. Dr. Gandhi will highlight the TAMP therapy platform and the opportunity it may give to LAPC patients as a potential targeted oncology option for treatment.
Dr. Gandhi will also discuss the status of the Company's ongoing Phase III TIGeR-PaC study, which is evaluating the use of the TAMP therapy platform with gemcitabine HCl in patients with LAPC. Additionally, he will review a recent publication in the international peer-reviewed journal, The Oncologist, of early-stage clinical data on the intra-arterial administration of gemcitabine HCl utilizing the TAMP including Phase I/II dose escalation safety study (RR1) and acquired data from a post-marketing post-treatment observational registry study (RR2).